The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
Abstract
With six therapies approved by the Food and Drug Association, chimeric antigen receptor (CAR) T cells have reshaped cancer immunotherapy. However, these therapies rely on ex vivo viral transduction to induce permanent CAR expression in T cells, which contributes to high production costs and long‐term side effects. Thus, this work aims to develop an in vivo CAR T cell engineering platform to streamline production while using mRNA to induce transient, tunable CAR expression. Specifically, an ionizable lipid nanoparticle (LNP) is utilized as these platforms have demonstrated clinical success in nucleic acid delivery. Though LNPs often accumulate in the liver, the LNP platform used here achieves extrahepatic transfection with enhanced delivery to the spleen, and it is further modified via antibody conjugation (Ab‐LNPs) to target pan‐T cell markers. The in vivo evaluation of these Ab‐LNPs confirms that targeting is necessary for potent T cell transfection. When using these Ab‐LNPs for the delivery of CAR mRNA, antibody and dose‐dependent CAR expression and cytokine release are observed along with B cell depletion of up to 90%. In all, this work conjugates antibodies to LNPs with extrahepatic tropism, evaluates pan‐T cell markers, and develops Ab‐LNPs capable of generating functional CAR T cells in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationLipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Human chimeric antigen receptor macrophages for cancer immunotherapy
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0462-y · Cited by 1,495
CAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
Self-citationDelivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102
CAR T Cells Produced in vivo to Treat Cardiac Injury
Rurik, J. G., Tombácz, I., Yadegari, A., Fernández, P. O. M., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2023) · HAL · Cited by 926
Self-citationSommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Tools for translation: non-viral materials for therapeutic mRNA delivery
Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799
Kauffman, K. J., Dorkin, J. R., Yang, J. H., Heartlein, M. W., DeRosa, F., Mir, F. F., Fenton, O. S., & Anderson, D. G. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b02497 · Cited by 796
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji, W., Reiman, D., Bonagofski, E., Wohlfahrt, M. E., Pillai, S. P. S., & Stephan, M. T. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.57 · Cited by 785
Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy
Oberli, M. A., Reichmuth, A. M., Dorkin, J. R., Mitchell, M. J., Fenton, O. S., Jaklenec, A., Anderson, D. G., Langer, R., & Blankschtein, D. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b03329 · Cited by 719
Self-citationBNT162b vaccines protect rhesus macaques from SARS-CoV-2
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03275-y · Cited by 694
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04246 · Cited by 636
Self-citationPolymers for gene delivery across length scales
Putnam, D. (2006) · Nature Materials · doi:10.1038/nmat1645 · Cited by 572
A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061283 · Cited by 531
Zhao, Y., Moon, E., Carpenito, C., Paulos, C. M., Liu, X., Brennan, A. L., Chew, A., Carroll, R. G., Scholler, J., Levine, B. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2880 · Cited by 450
T cell‐targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
Schmid, D., Park, C. G., Hartl, C. A., Subedi, N., Cartwright, A. N., Puerto, R. B., Zheng, Y., Maiarana, J., Freeman, G. J., Wucherpfennig, K. W., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01830-8 · Cited by 449
Parayath, N. N., Stephan, S. B., Koehne, A. L., Nelson, P. S., & Stephan, M. T. (2020) · Nature Communications · doi:10.1038/s41467-020-19486-2 · Cited by 446
Chen, D., Love, K. T., Chen, Y., Eltoukhy, A. A., Kastrup, C., Sahay, G., Jeon, A., Dong, Y., Whitehead, K. A., & Anderson, D. G. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301621z · Cited by 424
T cell migration, search strategies and mechanisms
Krummel, M. F., Bartumeus, F., & Gérard, A. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.16 · Cited by 423
Chen, J., Ye, Z., Huang, C., Qiu, M., Song, D., Li, Y., & Xu, Q. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2207841119 · Cited by 422
An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
Cooper, M. L., Choi, J., Staser, K., Ritchey, J. K., Devenport, J. M., Eckardt, K., Rettig, M. P., Wang, B., Eissenberg, L. G., Ghobadi, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0065-5 · Cited by 392
A guide to manufacturing CAR T cell therapies
Vormittag, P., Gunn, R., Ghorashian, S., & Veraitch, F. S. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.01.025 · Cited by 383
Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies
Marques, A. C., Costa, P. J., Velho, S., & Amaral, M. H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.035 · Cited by 349
Breaking Down the Barriers to Precision Cancer Nanomedicine
von Roemeling, C., Jiang, W., Chan, C. K., Weissman, I. L., & Kim, B. Y. S. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.07.006 · Cited by 330
Biological Gene Delivery Vehicles: Beyond Viral Vectors
Seow, Y., & Wood, M. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.41 · Cited by 327
Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device
Shepherd, S. J., Warzecha, C. C., Yadavali, S., El-Mayta, R., Alameh, M.-G., Wang, L., Weissman, D., Wilson, J. M., Issadore, D., & Mitchell, M. J. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c01353 · Cited by 317
Self-citationTombácz, I., Laczkó, D., Shahnawaz, H., Muramatsu, H., Natesan, A., Yadegari, A., Papp, T. E., Alameh, M.-G., Shuvaev, V., Mui, B. L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.004 · Cited by 296
Self-citationFenton, O. S., Kauffman, K. J., Kaczmarek, J. C., McClellan, R. L., Jhunjhunwala, S., Tibbitt, M. W., Zeng, M. D., Appel, E. A., Dorkin, J. R., Mir, F. F., et al. (2017) · Advanced Materials · doi:10.1002/adma.201606944 · Cited by 288
Ben Mkaddem, S., Benhamou, M., & Monteiro, R. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00811 · Cited by 283
Cytokines in CAR T Cell–Associated Neurotoxicity
Gust, J., Ponce, R., Liles, W. C., Garden, G. A., & Turtle, C. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577027 · Cited by 264
McKinlay, C. J., Benner, N. L., Haabeth, O. A., Waymouth, R. M., & Wender, P. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805358115 · Cited by 238
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Bouchkouj, N., Kasamon, Y. L., de Claro, R. A., George, B., Lin, X., Lee, S., Blumenthal, G. M., Bryan, W., McKee, A. E., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2743 · Cited by 226
Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells
Barrett, D. M., Zhao, Y., Liu, X., Jiang, S., Carpenito, C., Kalos, M., Carroll, R. G., June, C. H., & Grupp, S. A. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.070 · Cited by 220
Immunogenicity Risk Profile of Nanobodies
Ackaert, C., Smiejkowska, N., Xavier, C., Sterckx, Y. G. J., Denies, S., Stijlemans, B., Elkrim, Y., Devoogdt, N., Caveliers, V., Lahoutte, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632687 · Cited by 219
Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles
Ramishetti, S., Kedmi, R., Goldsmith, M., Leonard, F., Sprague, A. G., Godin, B., Gozin, M., Cullis, P. R., Dykxhoorn, D. M., & Peer, D. (2015) · ACS Nano · doi:10.1021/acsnano.5b02796 · Cited by 210
Ou, W., Thapa, R. K., Jiang, L., Soe, Z. C., Gautam, M., Chang, J.-H., Jeong, J.-H., Ku, S. K., Choi, H.-G., Yong, C. S., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.018 · Cited by 200
Biomaterials for vaccine-based cancer immunotherapy
Zhang, R., Billingsley, M. M., & Mitchell, M. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.008 · Cited by 200
Self-citationPovsic, T. J., Lawrence, M. G., Lincoff, A. M., Mehran, R., Rusconi, C. P., Zelenkofske, S. L., Huang, Z., Sailstad, J., Armstrong, P. W., Steg, P. G., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.058 · Cited by 197
Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement
Estapé Senti, M., de Jongh, C. A., Dijkxhoorn, K., Verhoef, J. J. F., Szebeni, J., Storm, G., Hack, C. E., Schiffelers, R. M., Fens, M. H., & Boross, P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.042 · Cited by 196
Cationic polymers for non-viral gene delivery to human T cells
Olden, B. R., Cheng, Y., Yu, J. L., & Pun, S. H. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.043 · Cited by 195
Imidazole‐Based Synthetic Lipidoids for In Vivo mRNA Delivery into Primary T Lymphocytes
Zhao, X., Chen, J., Qiu, M., Li, Y., Glass, Z., & Xu, Q. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202008082 · Cited by 179
Billingsley, M. M., Hamilton, A. G., Mai, D., Patel, S. K., Swingle, K. L., Sheppard, N. C., June, C. H., & Mitchell, M. J. (2022) · Nano Letters · doi:10.1021/acs.nanolett.1c02503 · Cited by 178
Self-citationBiomaterials for mRNA delivery
Islam, M. A., Reesor, E. K. G., Xu, Y., Zope, H. R., Zetter, B. R., & Shi, J. (2015) · Biomaterials Science · doi:10.1039/c5bm00198f · Cited by 176
Penaranda, C., Tang, Q., & Bluestone, J. A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100713 · Cited by 176
Kheirolomoom, A., Kare, A. J., Ingham, E. S., Paulmurugan, R., Robinson, E. R., Baikoghli, M., Inayathullah, M., Seo, J. W., Wang, J., Fite, B. Z., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121339 · Cited by 171
Granot-Matok, Y., & Peer, D. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.015 · Cited by 166
Alnylam launches era of RNAi drugs
Garber, K. (2018) · Nature Biotechnology · doi:10.1038/nbt0918-777 · Cited by 157
Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo
Zhou, J., Sun, L., Jia, Y., Wang, Z., Luo, T., Tan, J., Fang, X., Zhu, H., Wang, J., Yu, L., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.033 · Cited by 153
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
van Brummelen, E. M. J., Ros, W., Wolbink, G., Beijnen, J. H., & Schellens, J. H. M. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0061 · Cited by 150
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy
Swingle, K. L., Safford, H. C., Geisler, H. C., Hamilton, A. G., Thatte, A. S., Billingsley, M. M., Joseph, R. A., Mrksich, K., Padilla, M. S., Ghalsasi, A. A., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c12893 · Cited by 145
Self-citationNanoparticles for nucleic acid delivery: Applications in cancer immunotherapy
Mukalel, A. J., Riley, R., Zhang, R., & Mitchell, M. J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.040 · Cited by 145
Self-citationFoster, J., Choudhari, N., Perazzelli, J., Storm, J., Hofmann, T. J., Jain, P., Storm, P. B., Pardi, N., Weissman, D., Waanders, A. J., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.145 · Cited by 141
Self-citationMcHugh, M. D., Park, J. Y., Uhrich, R., Gao, W., Horwitz, D. A., & Fahmy, T. M. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.04.003 · Cited by 129
T Cell-Specific siRNA Delivery Using Antibody-Conjugated Chitosan Nanoparticles
Lee, J., Yun, K.-S., Choi, C. S., Shin, S.-H., Ban, H., Rhim, T., Lee, S. K., & Lee, K. Y. (2012) · Bioconjugate Chemistry · doi:10.1021/bc2006219 · Cited by 102
Brown, S. B., Wang, L. A., Jungels, R. R., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.10.003 · Cited by 93
Liu, Y., Chen, X., Han, W., & Zhang, Y. (2017) · Drugs of today · doi:10.1358/dot.2017.53.11.2725754 · Cited by 91
Rajan, P. K., Udoh, U. S., Sanabria, J. D., Banerjee, M., Smith, G., Schade, M. S., Sanabria, J. A., Sodhi, K., Pierre, S. V., Xie, Z., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238894 · Cited by 78
Research progress and applications of nanobody in human infectious diseases
Mei, Y., Chen, Y., Sivaccumar, J. P., An, Z., Xia, N., & Luo, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.963978 · Cited by 74
Structure and function of Fc receptors on macrophages and lymphocytes
Mellman, I., Koch, T., Healey, G. A., Hunziker, W., Lewis, V., Plutner, H., Miettinen, H. M., Vaux, D. J., Moore, K. W., & Stuart, S. G. (1988) · Journal of Cell Science · doi:10.1242/jcs.1988.supplement_9.3 · Cited by 67
RNA-based gene transfer for adult stem cells and T cells
Smits, E., Ponsaerts, P., Lenjou, M., Nijs, G., Bockstaele, D. R. V., Berneman, Z. N., & Tendeloo, V. F. V. (2004) · Leukemia · doi:10.1038/sj.leu.2403463 · Cited by 67
Dai, Z., Mu, W., Zhao, Y., Jia, X., Liu, J., Wei, Q., Tan, T., & Zhou, J. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.07.001 · Cited by 66
Berdeja, J. G., Lin, Y., Raje, N. S., Siegel, D. S. D., Munshi, N. C., Liedtke, M., Jagannath, S., Maus, M. V., Turka, A., Lam, L. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3010 · Cited by 57
Medical management of side effects related to CAR T cell therapy in hematologic malignancies
Namuduri, M., & Brentjens, R. J. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1183479 · Cited by 54
Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies
Su, S., Lei, A., Wang, X., Lu, H., Wang, S., Yang, Y., Li, N., Zhang, Y., & Zhang, J. (2022) · Cells · doi:10.3390/cells11101652 · Cited by 52
Domingues, R. G., Lago‐Baldaia, I., Pereira‐Castro, I., Fachini, J. M., Oliveira, L., Drpic, D., Lopes, N., Henriques, T., Neilson, J. R., Carmo, A. M., et al. (2016) · European Journal of Immunology · doi:10.1002/eji.201545663 · Cited by 46
Fleischer, L. C., Becker, S. A., Ryan, R. E., Fedanov, A., Doering, C. B., & Spencer, H. T. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.003 · Cited by 39
IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro
Zhang, H., Lv, X., Kong, Q., & Tan, Y. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2016005 · Cited by 37
Improving the Delivery of Drugs and Nucleic Acids to T Cells Using Nanotechnology
Lou, J. W. H., Heater, A., & Zheng, G. (2021) · Small Structures · doi:10.1002/sstr.202100026 · Cited by 14
Hartsell, A. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.544 · Cited by 6
Cited by
In vivo CAR T cell generation to treat cancer and autoimmune disease
Hunter, T. L., Bao, Y., Zhang, Y., Matsuda, D., Riener, R., Wang, A., Li, J. J., Soldevila, F., Chu, D. S. H., Nguyen, D. P., et al. (2025) · Science · doi:10.1126/science.ads8473 · Cited by 330
Peptide-Functionalized Lipid Nanoparticles for Targeted Systemic mRNA Delivery to the Brain
Han, E. L., Tang, S., Kim, D., Murray, A. M., Swingle, K. L., Hamilton, A. G., Mrksich, K., Padilla, M. S., Palanki, R., Li, J. J., et al. (2025) · Nano Letters · doi:10.1021/acs.nanolett.4c05186 · Cited by 158
Self-citation
Metadata
- Authors
- Billingsley, M. M., Gong, N., Mukalel, A. J., Thatte, A. S., El‐Mayta, R., Patel, S. K., Metzloff, A. E., Swingle, K. L., Han, X., Xue, L., Hamilton, A. G., Safford, H. C., Alameh, M., Papp, T. E., Parhiz, H., Weissman, D., & Mitchell, M. J.
- Venue
- Small
- Publisher
- Wiley
- Published
- 2023-12-10
- Volume
- 20
- Issue
- 11
- Pages
- e2304378-e2304378
- ISSN
- 1613-6810 (ISSN-L)
- 1613-6829
- OpenAlex
- W4389527549
- Cited by
- 268
- References
- 80
- FWCI
- 20.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.